Merck & Co., Inc.’s Keytruda (pembrolizumab) continues to set records within oncology. In 2019, alongside Revlimid (lenalidomide, in third place on this list), it became the first cancer drug to achieve more than $10bn in annual sales, before accelerating a further 30% to achieve its unmatched 2020 total.
This is all the more impressive considering Keytruda only made its market debut in 2014, and directly competes with nine...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?